Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Patent
1994-05-19
1995-12-19
Wax, Robert A.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
514 2, 514 13, 514 14, 530300, 530350, 530324, 530325, 530326, 530327, 530328, 530329, 530829, 530837, 530838, A61K 3802, C07K 200
Patent
active
054768390
ABSTRACT:
Several natural polypeptides (basophil granule proteins, "BGP") derived from the cytoplasmic granules of human basophils, and modified forms thereof, are described. These polypeptides, the DNA which encodes them and antibodies which recognize them, are useful as diagnostics for, and treatments for, pathologies involving inflammatory and IgE-mediated responses, parasitic and helminthic infections, hypersensitivity reactions and certain types of leukocytic leukemias.
REFERENCES:
patent: 4833092 (1989-05-01), Geysen
patent: 4935370 (1990-06-01), Franke
Denburg et al., "Heterogeneity of Human Peripheral Blood Eosinophil-Type Colonies: Evidence for a Common Basophil-Eosinophil Progenitor," Blood (1985) 66(2):312-318.
Stockinger et al., "Human Blood Basophils synthesize Interleukin-2 Binding Sites," Blood (1990) 75(9): 1820-1826.
Dvorak et al., "Isolation of the Cytoplasmic Granules of Guinea Pig Basophilic Leukocytes: Identification of Esterase and Protease Activities," J. Immuno. (1977) 119(1):38-46.
Denburg et al., "Partial Separation and Functional Characterization of Guinea Pig Basophil-Stimulating Factor," Int. Arch. Allergy Appl. Immunol. (1986) 79(3):312-319.
Weller et al., "Biochemical Characterization of Human Eosinophil Charcot-Leyden Crystal Protein (Lysophospholipase)," J. Bio. Chem. (1984) 259:15100-15105.
Durack et al., "Purification of human eosinophil-derived neurotoxin," Proc. Natl. Acad. Sci. (1981) 78:5165-5169.
Dvorak et al., "Ultrastructural Localization of the Charcot-Leyden Crystal Protein (Lysophospholipase) to Granules and Intragranular Crystals in Mature Human Basophils," Lab. Inv. (1989) 60:557-567.
Ackerman et al., "Localization of Eosinophil Granule Major Basic Protein in Human Basophils," J. Exp. Med. (1983) 158:946-961.
Wasmoen et al., "Biochemical and Amino Acid Sequence Analysis of Human Eosinophil Granule Major Basic Protein," J. Biol. Chem. (1988) 263:12559-12561.
Hunkapiller, "PTH Amino Acid Analysis," Applied Biosystems (1985) No. 14, pp. 1-27.
Geysen et al., "Use of peptide synthesis to probe viral antigens for epitopes to a resolution of a single amino acid," Proc. Natl. Acad. Sci. (USA) (1984) 81:3998-4002.
Bateman et al. (1990) Biochem. Biophys. Res. Comm. 173:1161-1168.
Long et al. (1984) Biochemistry 23:4828-4837.
Daher et al. (1988) Proc. Nat. Acad. Sci., USA 85:7327-7331.
Selsted et al. (1989) J. Biol. Chem. 264: 4003-4007.
Bhandari et al. (1992) Proc. Nat. Acad Sci, USA, 89:1715-1719.
Lerner, R. A. (1984) Adv. Inmmunol 36: 1-44.
Ogilvie et al., "Basophils and eosinophils in three strains of rats and in athymic (nude) rats following infection with the nematodes Nippostrongylus brasiliensis or Trichinella spiralis", Immunology (1980) 39:385-389.
Juhlin et al., "A New Syndrome Characterized by Absence of Eosinophils and Basophils", The Lancet (1977) 1:1233-1235.
Schwartz et al., "The Mast Cell and Mediators of Immediate Hypersensitivity", Immunological Diseases, Samter et al., (Eds.), Little Brown & Co. 4th Ed., pp. 157-201 (1988).
Solley et al., "The Late Phase of the Immediate Wheal and Flare Skin Reaction", The Journal of Clinical Investigation (1976) 58:408-420.
Charlesworth et al., "Cutaneous Late-Phase Response to Allegen", J. Clin. Invest. (1989) 83:1519-1526.
Dvorak et al., "Purification of Basophilic Leukocytes from Guinea Pig Blood and Bone Marrow", The Journal of Immunology (1974) 113(6):1694-1702.
Ackerman et al., "Formation of Charcot-Leyden Crystals by Human Basophils", Journal of Experimental Medicine (1982) 155:1597-1609.
Castells et al., "Evaluation of Human Peripheral Blood Leukocytes for Mast Cell Tryptase", The Journal of Immunology (1987) 138:2184-2189.
Newball et al., "Anaphylactic Release of a Basophil Kallikrein-like Activity", J. Clin. Invest. (1979) 64:466-475.
Orenstein et al., "Sulfated Glycosaminoglycans of Guinea Pig Basophilic Leukocytes", The Journal of Immunology (1978) 121(12):586-592.
Shoyab, M., et al., "Epithelins 1 and 2: Isolation and characterization of two cysteine-rich growth-modulating proteins" Proc. Natl. Acad. Sci. USA (1990) 87:7912-7916.
Galli et al., "Basophils and Mast Cells: Morphologic Insights into their Biology, Secretory Patterns, and Function", Prog. Allergy (1984) 34:1-141.
Brown et al., "Ablation of Immunity to Amblyomma Americanum by Anti-Basophil Serum: Cooperation Between Basophils and Eosinophils in Expression of Immunity to Ectoparasites (Ticks) in Guinea Pigs", The Journal of Immunology (1982) 129(2):790-796.
Gleich Gerald J.
Scott Randy W.
Wilde Craig G.
Bozicevic Karl
Bugaisky G. E.
Francis Carol L.
Incyte Pharmaceuticals Inc.
Mayo Foundation for Medical Education and Research
LandOfFree
Basophil granule proteins does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Basophil granule proteins, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Basophil granule proteins will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-992142